- A phase 1 trial of claudin 18.2-specific antibody-drug conjugate CMG901 in patients with advanced gastric/gastroesophageal junction cancer.Xu, Rui-Hua; Ruan, Dan-Yun; Zhang, Dong-Sheng; Liu, Fu-Rong; Luo, Su-Xia; Zhuang, Zhi-Xiang; Wang, Zhen-Ning; Liu, Fu-Nan; Zhang, Yan-Qiao; Yang, Jian-Wei; Chen, Zhen-Dong; Wang, Yong-Sheng; Wang, Jun-Ye; Liang, Xiao-Hua; Wu, Xiao-Jie; Zheng, Yu-Long; Liu, Jian; Shi, Xi; Liu, Wei; Chen, BoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2023-11 To 2023-11.
- A multicenter, phase 1 study of AB011, a recombinant humanized anti-CLDN18.2 monoclonal antibody, as monotherapy and combined with capecitabine and oxaliplatin (CAPOX) in patients with advanced solid tumors.Li, Jin; Pan, Hongming; Liu, Tianshu; Xu, Nong; Zhang, Yanqiao; Qin, Yanru; Shi, Jianhua; Liao, Dongcheng; Shen, Lin; Luo, Suxia; Pan, Yueyin; Zhao, Wei; Zheng, Yu; Zhuang, Rongyuan; Mao, Chenyu; Ma, Yue; Wang, Huamao; Li, ZonghaiGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 1
- EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumorsAggarwal, Charu; Azzoli, Christopher G.; Spira, Alexander I.; Solomon, Benjamin J.; Le, Xiuning; Rolfo, Christian; Planchard, David; Felip, Enriqueta; Wu, Yi-Long; Ahn, Myung-Ju; Seiwert, Tanguy Y.; Goto, Koichi; Azaro, Analia; Lissa, Delphine; Hamid, Oday; McGrath, Lara; Maudsley, Rhiannon; Arnaldez, Fernanda I.; Grenga, Italia; Massarelli, ErminiaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
9阅读
